Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases.
| Autor: | Achille A; Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy., Guarnieri G; Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy., Vianello A; UOC Fisiopatologia Respiratoria Ospedale-Università di Padova Via Giustiniani, Padova, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2024 Nov 27. Date of Electronic Publication: 2024 Nov 27. |
| DOI: | 10.1515/cclm-2024-1089 |
| Abstrakt: | Important advancements have been made in understanding the pathogenetic mechanisms underlying acute and chronic lung disorders. But although a wide variety of innovative biomarkers have and are being investigated, they are not largely employed to evaluate non-neoplastic lung diseases. The current work aims to examine the use of Krebs von den Lungen-6 (KL-6), a mucin-like glycoprotein predominantly expressed on the surface of type II alveolar epithelial cells (AEC2s), to evaluate the stage, response to treatment, and prognosis in patients with non-neoplastic lung disorders. Data analysis suggests that KL-6 can be utilized as an effective diagnostic and prognostic biomarker in individuals with interstitial lung disease and as a predictor of clinical outcomes in subjects with SARS-CoV-2-related pneumonia. Moreover, KL-6 can be reliably used in routine clinical settings to diagnose and predict the outcome of patients with chronic obstructive pulmonary disease (COPD) exacerbation. The optimal cut-off points within the European population should be defined to improve KL-6's diagnostic efficacy. (© 2024 Walter de Gruyter GmbH, Berlin/Boston.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|